JP2024517085A - 子宮漿液性がんを治療するためのｗｅｅ１化合物 - Google Patents

子宮漿液性がんを治療するためのｗｅｅ１化合物 Download PDF

Info

Publication number
JP2024517085A
JP2024517085A JP2023562607A JP2023562607A JP2024517085A JP 2024517085 A JP2024517085 A JP 2024517085A JP 2023562607 A JP2023562607 A JP 2023562607A JP 2023562607 A JP2023562607 A JP 2023562607A JP 2024517085 A JP2024517085 A JP 2024517085A
Authority
JP
Japan
Prior art keywords
subject
administered
effective amount
therapeutically effective
dosing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023562607A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022221143A5 (https=
JP2024517085A5 (https=
Inventor
ポルター，フィリップ
ヴォリオティス，ディミトリオス
ロドリゲス ヴィアナ，マルクス
ドネイト，フェルナンド
ジョン，ペトリュス ルドルフ デ
アブディ サマター，アフメド
デュアン バンカー，ケビン
キンファ ファン，ピーター
Original Assignee
リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー filed Critical リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー
Publication of JP2024517085A publication Critical patent/JP2024517085A/ja
Publication of JPWO2022221143A5 publication Critical patent/JPWO2022221143A5/ja
Publication of JP2024517085A5 publication Critical patent/JP2024517085A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
JP2023562607A 2021-04-12 2022-04-08 子宮漿液性がんを治療するためのｗｅｅ１化合物 Pending JP2024517085A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163174005P 2021-04-12 2021-04-12
US202163174004P 2021-04-12 2021-04-12
US63/174,004 2021-04-12
US63/174,005 2021-04-12
PCT/US2022/024079 WO2022221143A1 (en) 2021-04-12 2022-04-08 Wee1 compound for treating uterine serous carcinoma

Publications (3)

Publication Number Publication Date
JP2024517085A true JP2024517085A (ja) 2024-04-19
JPWO2022221143A5 JPWO2022221143A5 (https=) 2025-04-09
JP2024517085A5 JP2024517085A5 (https=) 2025-04-09

Family

ID=83640600

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023562607A Pending JP2024517085A (ja) 2021-04-12 2022-04-08 子宮漿液性がんを治療するためのｗｅｅ１化合物

Country Status (7)

Country Link
US (1) US20240197743A1 (https=)
EP (1) EP4322958A4 (https=)
JP (1) JP2024517085A (https=)
AU (1) AU2022259496A1 (https=)
CA (1) CA3213804A1 (https=)
TW (1) TW202304455A (https=)
WO (1) WO2022221143A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020384291A1 (en) 2019-11-15 2022-05-26 Recurium Ip Holdings, Llc Chiral synthesis of a tertiary alcohol
BR112023000350A2 (pt) 2020-07-09 2023-03-28 Recurium Ip Holdings Llc Sais e formas de um inibidor de wee1
EP4615459A4 (en) * 2022-11-08 2026-04-29 Zeno Man Inc Intermittent dosing regimen for azenosertib in treating cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019173082A1 (en) * 2018-03-09 2019-09-12 Zeno Royalties & Milestones, LLC Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12318452B2 (en) 2018-09-27 2025-06-03 Dana-Farber Cancer Institute, Inc. Degraders of WEE1 kinase
WO2020210320A1 (en) * 2019-04-11 2020-10-15 Recurium Ip Holdings, Llc Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019173082A1 (en) * 2018-03-09 2019-09-12 Zeno Royalties & Milestones, LLC Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
[ONLINE], vol. [検索日 2026年2月12日], JPN6026009161, 10 April 2021 (2021-04-10), ISSN: 0005813168 *
[ONLINE], vol. [検索日 2026年2月12日], JPN6026009162, 22 March 2021 (2021-03-22), ISSN: 0005813169 *
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, vol. 27, no. 3, JPN6026009160, 2017, pages 452 - 458, ISSN: 0005813171 *
JOURNAL OF CLINICAL ONCOLOGY, vol. 39, no. 14, JPN6026009158, 12 April 2021 (2021-04-12), pages 1531 - 1539, ISSN: 0005813167 *
OBSTETRICS AND GYNECOLOGY INTERNATIONAL, vol. 2013, no. 828165, JPN6026009159, 2013, pages 1 - 10, ISSN: 0005813170 *

Also Published As

Publication number Publication date
AU2022259496A1 (en) 2023-10-12
TW202304455A (zh) 2023-02-01
EP4322958A4 (en) 2025-04-09
WO2022221143A1 (en) 2022-10-20
US20240197743A1 (en) 2024-06-20
CA3213804A1 (en) 2022-10-20
EP4322958A1 (en) 2024-02-21

Similar Documents

Publication Publication Date Title
JP2024517085A (ja) 子宮漿液性がんを治療するためのｗｅｅ１化合物
JP6294889B2 (ja) ウイルス疾患の処置におけるｍｅｋ阻害物質
EP4110326B1 (en) Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
US20240335447A1 (en) Wee1 inhibitor for cancer
JP2012236857A (ja) 抗ｅｇｆｒ療法に二次的な皮疹の予防および処置のためのビタミンｋ
TW202304424A (zh) 包含依維莫司和安森司群的組合
JP2024539872A (ja) Ｗｅｅ１阻害剤及びｄｎａ損傷応答（ｄｄｒ）阻害剤を含む併用療法
KR20210024475A (ko) 질환 치료를 위한 릴루졸 경구 붕해 정제의 용도
JP2024538117A (ja) Ｗｅｅ１阻害剤と抗ｃｄ４７抗体との組み合わせ。
US20250205240A1 (en) Combinations
US20250208149A1 (en) Wee1 compound for treating uterine serous carcinoma
JP7115671B2 (ja) 新規なｍｃｔ４阻害剤及びその使用
JP2001512447A (ja) アミホスチンの投与方法
WO2021032212A1 (zh) 靶向组织微环境中衰老细胞的抗衰老药物d/a及其应用
WO2021023291A1 (zh) 原黄素在肺癌治疗中的应用
CN117500505A (zh) 用于治疗子宫浆液性癌的wee1化合物
CN117357534A (zh) 包含维甲酸的药物组合物在制备治疗肝细胞癌伴腹腔转移的药物中的用途
TW202308641A (zh) 用於治療癌症之方法及包含cdk抑制劑之給藥方案
EP4452275B1 (en) Combination of cisplatin and elimusertib for the treatment of pediatric liver cancers
JP2014506904A (ja) γセクレターゼ阻害剤の投与方法
CN100455289C (zh) 孟德拉明类抗癌药
WO2025056747A1 (en) Combination of a wee1 inhibitor and a pkmyt1 inhibitor
WO2024246824A1 (en) Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer
EP4003361A1 (en) Cuptsm for the treatment of neurodegenerative disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250401

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250401

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260310